Lymphoid and lymphoproliferative cells

Lymphoid and lymphoproliferative cells refer to the diverse population of lymphocytes—including B cells, T cells, and natural killer (NK) cells—and their pathologically expanding counterparts in disease states (NIH, 2023). These cells are the primary effectors of the adaptive immune system, facilitating antigen recognition, antibody secretion, and direct cellular cytotoxicity (StatPearls, 2024). In lymphoproliferative disorders, these cells escape normal regulatory mechanisms, leading to malignancies such as lymphomas and leukemias, or contributing to systemic autoimmune conditions (National Cancer Institute, 2023). While this term describes a cellular lineage rather than a discrete molecular target, it serves as the biological context for numerous high-value therapeutic targets like CD20, CD19, and Bruton's tyrosine kinase (BTK) (PubChem, 2024). Drugs interacting with these cells range from monoclonal antibodies that induce cell depletion to small molecule inhibitors that disrupt survival signaling pathways. Consequently, therapeutic success is often measured by the selective elimination of these cells or the restoration of normal immune homeostasis.

Other names

LymphocytesLymphoid lineage cellsLymphoproliferative disorder cellsLymphoid cells

Therapeutic agents typically target specific surface markers (e.g., CD20) to induce antibody-dependent cellular cytotoxicity, or inhibit intracellular kinases (e.g., BTK) and anti-apoptotic proteins (e.g., BCL-2) to prevent proliferation and survival.